CLOZAPINE DISPOSITION COVARIES WITH CYP1A2 ACTIVITY DETERMINED BY A CAFFEINE TEST

被引:259
作者
BERTILSSON, L
CARRILLO, JA
DAHL, ML
LLERENA, A
ALM, C
BONDESSON, U
LINDSTROM, L
DELARUBIA, IR
RAMOS, S
BENITEZ, J
机构
[1] KAROLINSKA INST,HUDDINGE HOSP,DEPT MED LAB SCI & TECHNOL,DIV CLIN PHARMACOL,S-14186 HUDDINGE,SWEDEN
[2] UNIV EXTREMADURA,SCH MED,DEPT PHARMACOL,E-06071 BADAJOZ,SPAIN
[3] UPPSALA UNIV,PSYCHIAT RES CTR,S-75017 UPPSALA,SWEDEN
关键词
CLOZAPINE; CAFFEINE; CYP1A2;
D O I
10.1111/j.1365-2125.1994.tb04385.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
In a previous study we showed that the disposition of clozapine after a single oral dose is unrelated to either debrisoquine or S-mephenytoin hydroxylation polymophism. The same 14 healthy subjects studied in that investigation were given 150 mg of caffeine. The reciprocal of plasma clozapine AUC (0,24), was correlated with an index of the N3-demethylation of caffeine (r(s) = 0.84; P = 0.0024), used as a measure of cytochrome P4501A2 (CYP1A2) activity. N1- and N7-demethylation indices of caffeine also reflect CYP1A2 activity and were also correlated with clozapine clearance (r(s) = 0.89 and 0.85; P = 0.0013 and 0.0023; respectively). No significant relationships with xanthine oxidase and N-acetyl transferase activity, also assessed by a caffeine test, were found. This study suggests that clozapine is metabolised by CYP1A2 to a major extent.
引用
收藏
页码:471 / 473
页数:3
相关论文
共 50 条
  • [31] Impact of Smoking, Smoking Cessation, and Genetic Polymorphisms on CYP1A2 Activity and Inducibility
    Dobrinas, M.
    Cornuz, J.
    Oneda, B.
    Serra, M. Kohler
    Puhl, M.
    Eap, C. B.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 90 (01) : 117 - 125
  • [32] Impact of switching to a heat-not-burn tobacco product on CYP1A2 activity
    van der Plas, Angela
    Pouly, Sandrine
    Blanc, Nicolas
    Haziza, Christelle
    de La Bourdonnaye, Guillaume
    Titz, Bjorn
    Hoeng, Julia
    Ivanov, Nikolai V.
    Taranu, Brindusa
    Heremans, Annie
    TOXICOLOGY REPORTS, 2020, 7 : 1480 - 1486
  • [33] Analysis of urinary caffeine metabolites by HPLC-DAD: the use of metabolic ratios to assess CYP1A2 enzyme activity
    Caubet, MS
    Elbast, W
    Dubuc, MC
    Brazier, JL
    JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2002, 27 (1-2) : 261 - 270
  • [34] Evaluation of caffeine as an in vivo probe for CYP1A2 using measurements in plasma, saliva, and urine
    Carrillo, JA
    Christensen, M
    Ramos, SI
    Alm, C
    Dahl, ML
    Benítez, J
    Bertilsson, L
    THERAPEUTIC DRUG MONITORING, 2000, 22 (04) : 409 - 417
  • [35] Caffeine and paraxanthine HPLC assay for CYP1A2 phenotype assessment using saliva and plasma
    Perera, Vidya
    Gross, Annette S.
    McLachlan, Andrew J.
    BIOMEDICAL CHROMATOGRAPHY, 2010, 24 (10) : 1136 - 1144
  • [36] Evidence from a population pharmacokinetics analysis for a major effect of CYP1A2 activity on inter- and intraindividual variations of clozapine clearance
    Dailly, E
    Urien, S
    Chanut, E
    Claudel, B
    Guerra, N
    Fernandez, C
    Jolliet, P
    Bourin, M
    PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2002, 26 (04) : 699 - 703
  • [37] Influence of genetic polymorphisms, smoking, gender and age on CYP1A2 activity in a Turkish population
    Gunes, Arzu
    Ozbey, Gul
    Vural, Elif Hilal
    Uluoglu, Canan
    Scordo, Maria Gabriella
    Zengil, Hakan
    Dahl, Marja-Liisa
    PHARMACOGENOMICS, 2009, 10 (05) : 769 - 778
  • [38] Effects of the aqueous extract from Salvia miltiorrhiza Bunge on caffeine pharmacokinetics and liver microsomal CYP1A2 activity in humans and rats
    Wang, Xin
    Yeung, John H. K.
    JOURNAL OF PHARMACY AND PHARMACOLOGY, 2010, 62 (08) : 1077 - 1083
  • [39] Caffeine N3-demethylation (CYP1A2) in a population with an increased exposure to polychlorinated biphenyls
    Maria Skaalum Petersen
    Jónrit Halling
    Per Damkier
    Flemming Nielsen
    Philippe Grandjean
    Pál Weihe
    Kim Brøsen
    European Journal of Clinical Pharmacology, 2006, 62 : 1041 - 1048
  • [40] Increased clozapine plasma concentrations and side effects induced by smoking cessation in 2 CYP1A2 genotyped patients
    Bondolfi, G
    Morel, F
    Crettol, SV
    Rachid, F
    Baumann, P
    Eap, CB
    THERAPEUTIC DRUG MONITORING, 2005, 27 (04) : 539 - 543